RxDoctor Payments Data

Eugene Valsky, MD

Internal Medicine · Plymouth, MANPI 1255398475

Payments from drug & device makers

$5,833in general payments, 2019–2025

Across 294 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$710
  • Pfizer$602
  • Amgen$580
  • Johnson & Johnson$545
  • Boehringer Ingelheim$484
  • E.r. Squibb & Sons, L.L.C.$463
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,824100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,833 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$247,942
Medicare patients
2,491
Services billed
5,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban551$754,139
OzempicSemaglutide170$177,465
XareltoRivaroxaban96$119,565
JardianceEmpagliflozin80$105,891
EntrestoSacubitril/Valsartan57$71,583
Repatha SureclickEvolocumab39$42,834
Repatha PushtronexEvolocumab25$22,644
TrulicityDulaglutide21$22,600
Rosuvastatin Calcium456$20,299
BrilintaTicagrelor25$19,753
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,248
Ezetimibe250$11,528
Metoprolol Succinate527$10,570
Praluent PenAlirocumab11$9,292
Atorvastatin Calcium636$9,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$602$754,139551 claims
Novo NordiskOzempic$190$177,465170 claims
Johnson & JohnsonXarelto$545$119,56596 claims
Boehringer IngelheimJardiance$484$105,89180 claims
NovartisEntresto$710$71,58357 claims
AstraZenecaBrilinta$236$19,75325 claims
GSKTrelegy Ellipta$94$12,24811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Plymouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →